Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

SPDR Series Trust - SPDR S&P Biotech ETF XBI

The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index derived from the biotechnology segment of a U. In seeking to track the performance of the S&P Biotechnology Select Industry Index (the index), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index (S&P TMI).


ARCA:XBI - Post by User

SPDR Series Trust - SPDR S&P Biotech ETF
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
  • GwenTracyX
Post by GwenTracyon Apr 16, 2022 11:15am
147 Views
Post# 34607467

FSD Pharma Inc: Lucid MS Video

FSD Pharma Inc: Lucid MS Video


FSD Pharma is delighted to announce pre-clinical findings indicating the efficacy of Lucid-MS, its flagship medication candidate, in treating Multiple Sclerosis. Lucid-MS's therapeutic potential is an industry first, and we'd like to provide visual evidence of functional recovery in pre-clinical individuals in this video!

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities